Nuvectis Pharma, Inc. (NVCT) vs Phathom Pharmaceuticals, Inc. (PHAT)

A side-by-side comparison of Nuvectis Pharma, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NVCT

Nuvectis Pharma, Inc.

$531M

$20.01HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT

PHAT

Phathom Pharmaceuticals, Inc.

$533M

$6.59HealthcareDelayed quote: Oct 6, 2026, 2:15 PM EDT

Total return — NVCT vs PHAT

growth of $100 · dividends reinvested · last 5y

NVCT +558.2% (+45.8%/yr)PHAT -59.2% (-16.4%/yr)NVCT compounded faster over this window

Log scale — wide-divergence pair

NVCT PHAT

NVCT vs PHAT: by the numbers

•PHAT is the larger company ($533M vs $531M market cap).
•Both run net losses; NVCT's is the smaller (0.00% vs -41.34% net margin).

Metrics side by side

Valuation

Metric	NVCT	PHAT
P/S ratio	N/A	2.22
P/B ratio	58.47	N/A

Profitability

Metric	NVCT	PHAT
Gross margin	0.00%	82.92%
Operating margin	0.00%	-91.36%
Net margin	0.00%	-41.34%
ROE	-306.61%	N/A
ROIC	-317.86%	-23.45%

Growth (annualized)

Metric	NVCT	PHAT
Total return CAGR (5Y)	N/A	-26.93%

Go deeper

Full NVCT analysis Full PHAT analysis Interactive comparison tool

Dig into the metrics

Nuvectis Pharma ROE Phathom Pharmaceuticals ROE Nuvectis Pharma operating margin Phathom Pharmaceuticals operating margin Nuvectis Pharma revenue growth Phathom Pharmaceuticals revenue growth Nuvectis Pharma free cash flow Phathom Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.